WO1998030571A1 - Preparation electrocinetique d'echantillons - Google Patents
Preparation electrocinetique d'echantillons Download PDFInfo
- Publication number
- WO1998030571A1 WO1998030571A1 PCT/EP1997/007306 EP9707306W WO9830571A1 WO 1998030571 A1 WO1998030571 A1 WO 1998030571A1 EP 9707306 W EP9707306 W EP 9707306W WO 9830571 A1 WO9830571 A1 WO 9830571A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- nucleic acid
- microchannel
- analysis
- macromolecules
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 97
- 102000039446 nucleic acids Human genes 0.000 claims description 97
- 150000007523 nucleic acids Chemical class 0.000 claims description 97
- 239000012528 membrane Substances 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 52
- 238000004458 analytical method Methods 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 241000700605 Viruses Species 0.000 claims description 35
- 229920002521 macromolecule Polymers 0.000 claims description 31
- 241000894006 Bacteria Species 0.000 claims description 21
- 238000002955 isolation Methods 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 5
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- -1 polytetrafluoroethylene Polymers 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 claims description 2
- 239000003365 glass fiber Substances 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229920002492 poly(sulfone) Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 238000003908 quality control method Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 42
- 239000000872 buffer Substances 0.000 description 41
- 230000007717 exclusion Effects 0.000 description 18
- 239000000975 dye Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 238000001212 derivatisation Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 238000001917 fluorescence detection Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 150000001450 anions Chemical class 0.000 description 7
- 238000001493 electron microscopy Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000009830 intercalation Methods 0.000 description 6
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000012062 aqueous buffer Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000008366 buffered solution Substances 0.000 description 4
- 238000005251 capillar electrophoresis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 230000003196 chaotropic effect Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001506 fluorescence spectroscopy Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000003014 ion exchange membrane Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 239000012811 non-conductive material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008051 TBE buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000004557 single molecule detection Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- OFJBYLCQNJHFMI-UHFFFAOYSA-N 2,5-dihydro-1,2-oxazole Chemical compound C1ONC=C1 OFJBYLCQNJHFMI-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- ONMOULMPIIOVTQ-UHFFFAOYSA-N 98-47-5 Chemical compound OS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 ONMOULMPIIOVTQ-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 1
- 240000003801 Sigesbeckia orientalis Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000787 affinity precipitation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000012305 analytical separation technique Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000014670 detection of bacterium Effects 0.000 description 1
- 230000010244 detection of fungus Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005363 electrowinning Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 1
- 238000003234 fluorescent labeling method Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002218 isotachophoresis Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44743—Introducing samples
Definitions
- Biomacromolecules such as Proteins and nucleic acids, but also small particles such as viruses and bacteria, are of great importance both diagnostically and for medical research.
- the established methods for characterizing these substances from biological matrices are partly. very complex.
- the target nucleic acid is isolated for nucleic acid analyzes, then amplified and evaluated using a suitable analysis method. Isolation is time consuming and difficult to automate.
- the nucleic acid In order to obtain sufficient amounts of nucleic acid for the established analytical methods, the nucleic acid must be amplified in a further step. So far, only the polymerase chain reaction (PCR) has found wider application.
- Isolation from a pure bacterial culture is a simple case for obtaining nucleic acid: in the case of E. coli, alkaline lysis releases the nucleic acid; After centrifugation and neutralization, this crude product can be used directly for PCR batches (Rolfs, A. et al. PCR: Clinical Diagnosis and Research,
- sample material for medical diagnostics is more heterogeneous; Blood, urine, cerebrospinal fluid, swab material, sputum, tissue samples, faeces, e.g. call for specific digestion methods, which in turn depend on the question
- Silicon microparticles which can also be embedded in membranes, can also be used for nucleic acid purification (WO 95/34569).
- Ion exchange membranes US 832284
- chemically modified silica phases EP
- an isolation step usually follows the isolation of the nucleic acids (EP 229701).
- Viruses are usually isolated and concentrated using the following methods: ultracentrifuge, electroextraction, size exclusion separation, affinity chromatography and precipitation (Polson, Alfred, Prep. Biochem., 1993; 23, Dekker, New York,
- Bacteria are usually separated and raised by spreading on nutrient media.
- immunological methods eg by fluorescent labeling -
- nucleic acid determination methods after cell lysis - are available.
- Capillary electrophoretic analysis methods have been used for several years to analyze biological macromolecules such as proteins (WO 93/22665), nucleic acids (Heller, C, J. Chromatogr. A, 1995, 698, 19-31) and more recently also viruses (DE 4438833) Detection is carried out either directly with UV or by means of fluorescence detection after marking the macromolecules (Pentoney, SL, Jr, et al Handbook of Capdlary Electrophoresis, S 147, Landers, JP (Ed) Boca Raton, CRC
- a fundamental disadvantage of the CE is the low injection volume, which is only a few nanoliters. There are numerous attempts to compensate for this disadvantage (St. Claire R.L., Anal. Chem. 1996, 68, 569R-586R). This includes isotachophoretic concentration and stacking, both of which focus the sample components in the injection volume.
- a patent was filed by Guzmann in 1993 for a specific solid phase adsorption in the capillary for sample concentration (WO 93/05390). Specific compounds in a sample are held or allowed to pass through specific molecular interactions. A further development of these methods was developed by Tomlinson et al. made with the membrane preconcentration capillary electrophoresis (Tomlinson, A.J., et al. J. High
- Capillary array electrophoresis was developed by various working groups, mainly for nucleic acid sequencing, and a patent application was also filed in part (WO 96/04547).
- fluorescent molecules were controlled and analyzed depending on the voltage.
- Micromachines were also patented on the basis of chip technology, which enables process control of solutions for synthetic or analytical purposes through a network of channels and electrical switches (WO 96/15450).
- Amplification-free nucleic acid analyzes
- Fluorescence correlation spectroscopy was also used for biological screening methods using single molecule detection (EP 731173). High throughput nucleic acid sequencing is also processed based on this technology (Harding, J.D., et al. Trends in Biotechnology, 1992, 10, 55-57). These methods are based on the detection of a single fluorescent molecule in a very small volume element.
- an automated method should be developed that allows macromolecules (nucleic acids, proteins, viruses and bacteria) from biological materials, such as e.g. Blood, blood plasma, serum, cerebrospinal fluid, urine, tissue samples, plants, cells, cell supernatants etc. and preparations from them to be isolated, concentrated and made available for analysis.
- biological materials such as e.g. Blood, blood plasma, serum, cerebrospinal fluid, urine, tissue samples, plants, cells, cell supernatants etc. and preparations from them to be isolated, concentrated and made available for analysis.
- the central component of the sample preparation module is a thermostattable microchannel with an inserted membrane.
- This channel filled with a conductive liquid, is in contact with replaceable or fixed on both sides Installed vessels
- a potential difference between the sample vessels charged molecules can be mobilized electrophoretically.
- the possibility of applying a pressure difference can also generate a laminar flow in the microchannel.
- a membrane (2) is introduced into a microchannel (1) and is suitable for retaining the desired macromolecule.
- a pressure difference (6) and / or a voltage (5) to the ends of the microchannel (3,4), part of the sample becomes injected into the channel (Fig. 1) The injection is continued until there is a sufficient amount of the desired macromolecule in the microchannel.
- the injection can be carried out be matched to the desired target molecule so that either only the desired macromolecule gets into the channel or is held by the membrane
- the microchannel has an inner diameter of 10 - 100 ⁇ m and a total length of 3 - 50 cm.
- the microchannel is made of an electrically non-conductive material such as polymer, ceramic, glass or quartz. In principle, all are synthetic
- the polymer must be inside the buffer solutions used and is ideally transparent for optical detection methods (e.g. polycarbonate, polyester acrylate, polymethacrylate, polyurethane, polyacrylamide) but also PTFE is suitable.
- the channel can be coated on the inside with a polymer in order to obtain favorable surface properties (e.g. polyacrylamide, silanol or polyvinyl alcohol)
- membranes can be used that work on the principle of large size exclusion (ultrafiltration membrane).
- the large size exclusion range must be adapted to the molecular size of the macromolecule. Range, for large nucleic acids and viruses, down to 0.45 mm, for bacteria and cells the membranes are microstructured polymers, preferably polyether sulfone (PES), polyester, fleece-based acrylic polymer, polytetrafluoroethylene (PTFE), polysulfone, polypropylene (PP), glass fiber, nylon or polycarbonate.
- PES polyether sulfone
- PTFE polytetrafluoroethylene
- PP polypropylene
- glass fiber nylon or polycarbonate
- ion exchange membranes and adsorption phases can be used. The choice of these membranes depends on the type of
- the injected macromolecule is concentrated in front of or in the membrane (2) by applying a pressure difference (6) and / or a voltage (5) (Fig. 2).
- the desired macromolecule is then in a volume of a few nanoliters.
- Pressure difference (6) and / or a voltage (5) are brought into the microchannel (1) (Fig. 3).
- the conditions are chosen so that the target molecule remains concentrated. In this way, the target molecule can be modified enzymatically or chemically and / or specifically recognized by hybridization or immunological recognition.
- the ability of the microchannel (1) to be thermostatted and the ability to change the reagent tubes several times allows complex implementations and cyclical processes. In this modification step, any derivatization reactions that may be necessary for fluorescence, chemiluminescence or laser-induced fluorescence detection are carried out.
- the required reaction temperatures are achieved by thermostatting the microchannel (1).
- either appropriately tempered air or liquid is directed past the microchannel.
- the wall thickness of the microchannel is chosen so that sufficient heat dissipation is ensured.
- the target molecule After optimally changing the reagent vessels (8,9) against the buffer vessels (10,1 1), the target molecule is mobilized by applying a pressure difference (6) and / or a voltage (5) (Fig. 4).
- optical detection methods (12) such as Absorption or fluorescence, the molecule can be determined analytically directly in the microchannel (1) (13)
- the analog detection methods are available as in the CE (St.Claire RL, Anal. Chem. 1996, 68, 569R-586R)
- the microchannel is either made complete or transparent at one point for optical radiation.
- the transmission of the excitation radiation and the fluorescent radiation must be ensured. These are preferably the non-conductive materials explained at the beginning.
- the fluorescent radiation is perpendicular or at a defined angle of 0-180 ° measured in reflection to the irradiation wavelength.
- the irradiation is preferably at 45 ° or 90 °.
- the highly concentrated analysis target is, however, also available for further analysis (FIG. 5).
- the target molecule can thus be fractionated into the analysis vessel (14) or into or onto any other analysis target
- the analytical vessel (14) contains 1-1000 ml of a buffer suitable for further analysis.
- a buffer suitable for further analysis is PBS buffer, Tris / borate or a tris-glycine buffer.
- the analysis vessel (14) can also be a planar analysis target, for example a mass spectrometric sample holder. The electrical contact is either made directly via the conductive one
- Analysis target reached or by wetting the surface between the electrode and microchannel with an electrically conductive liquid.
- the concentrated target molecule can be brought into further channels for further analysis or conversion by switching over pressure or voltage and is therefore directly compatible with the CE chip technology (WO 96/04547)
- the highly concentrated macromolecule is eluted in less than a microliter and can be applied directly to suitable liquid matrices or to solid sample carriers
- a schematic representation of the parallel structure is shown in FIG. 6.
- the microchannels (1) are produced from non-conductive materials, such as polymer, ceramic, glass, quartz or ceramic (15), and are coated if necessary.
- the channel blocks are joined with an intermediate membrane layer (2) , so that the channels meet on the membrane The arrangement of the channels depends on the
- thermostatic elements may be introduced to dissipate the Joule heat.
- the channels are tapered at the ends so that they can be inserted into the respective vessels or are tightly connected to permanently installed vessels.
- electrodes and supplied with a high voltage source are used for electrical contact, either on attached to the channel ends or in the vessels.
- channels are placed in the analysis block that are perpendicular to the direction and between the levels of the microchannels. These channels allow air or liquid to be pumped at a suitable temperature
- the height of the channel corresponds to the dimension of the microchannel (10-100 ⁇ m), so that the Joule heat can still be dissipated well.
- the width of the channel (100 ⁇ m to 10 mm) allows rivers up to 10 3 higher than in the microchannel (1)
- the membrane is clamped between the module blocks (15).
- the entire module is 3 to 10 cm long, 1 to 50 mm wide and 0.1 to 50 mm thick
- the channel ends are in turn connected either to exchangeable or permanently installed sample vessels.
- a parallel arrangement can also be used to achieve an analog structure as in FIG. 6.
- the macromolecules are concentrated in the channel (16) and then transferred via the transfer channel (17) to the microchannel and analogously the method from FIGS. 1-6 further processed.
- the schematic enrichment of macromolecules with this rapid concentration is described below using the example of nucleic acids Nucleic acid from saline solution is enriched by applying a voltage to the flat channel (16) (Fig. 8a). In addition to the excess of small anions (small black balls), the nucleic acid is also injected from the sample. The anionic molecules migrate through the membrane (2 ) and are thus removed from the nucleic acid.
- modification reactions can also be carried out simultaneously on the concentrated macromolecule
- Nucleic acid is released from the sample to be examined using a suitable, established method (lysis, hydrolysis, ultrasound, etc.) and mixed with a suitable acidic extraction buffer.
- the buffer must be designed in such a way that non-nucleotide components of the solution do not carry an anionic excess charge below one pH
- a value of approx. 5 shows that proteins no longer have a negative excess charge.
- Inorganic acids such as hydrochloric acid, phosphoric acid or sulfuric acid as well as organic phosphoric acid derivatives or sulfonic acids can be used.
- a polymer-bound, acidic ion exchanger eg polystyrene sulfonic acid
- the acidic pH value is reached without additional anions being introduced into the solution. The electrokinetic nucleic acid extraction is thereby promoted
- the nucleic acid is extracted electrophoretically from this acid buffered solution.
- an electrode is introduced into the solution and brought to cationic potential.
- the electrode in the buffer vessel (4) (FIG. 1) is brought to anodic potential and the Microchannel (1) is filled with an electrically conductive liquid.
- the composition of the electrolyte depends on the type of immobilization technique. It is preferably an aqueous buffer based on borate, phosphate or citrate. Glycine is also a suitable buffer ion.
- the buffer concentration is between 10 and 100 mmol / 1.
- the pH is between 2.5 and 8.5.
- a modifier, preferably a chaotropic agent, such as urea is optionally added in molar concentration.
- the task can be carried out using UV or fluorescence detection - according to the previous one
- Derivatization - can be followed in the microchannel (1).
- the extracted nucleic acid is immobilized and concentrated in the channel with the aid of the membrane introduced while maintaining the tension (FIG. 2).
- soft anion exchangers for example based on amines, are also suitable for nucleic acids. They are preferably alkylamine, imidazole or pyrollidone-substituted polymers.
- the nucleic acids can also be retarded by adsorption on membranes.
- the membranes contain nanoparticles, preferably silica-based or metal oxide pigments.
- the nucleic acid concentrated to a few nanoliters can be modified and analyzed in many ways (FIG. 3).
- the open channel system allows reagents to be added and removed using pressure or tension. The polarity of the voltage is maintained as in the extraction and focusing. Combined with a suitable temperature control, enzymatic cleavages, Sanger sequencing, gene probe hybridization, but also PCR reactions are possible in the microsystem.
- the nucleic acid can be labeled with intercalating dyes.
- fluorescent derivatives such as ethidium bromide, acridine orange, or their dimers, such as 1,1 '- (4,4,7,7-tetramethyl-4,7diazaundecamethylene) -bis-4- [3-methyl-2 , 3-dihydromethyl- (benzo-l, 3-oxazole) -2methylidene] quinolinium
- Tetraiodide (YOYO)
- the choice of the dye depends primarily on the selected detection unit YOYO is ideal, for example, for fluorescence detection after excitation with an argon laser, while the corresponding YOPRO dimer is ideally suited to the infrared laser. These dyes are also characterized by this from that hardly
- the positively charged YOYO can be introduced electrokinetically, for example, from the reaction vessel (9) with the connection of the focusing voltage
- the gene probe consists of a nucleotide sequence that is complementary to the target nucleic acid and carries one or more fluorescent dyes.
- the choice of the dye is primarily based on the selected detection unit used after excitation with an argon laser
- Enzyme-catalyzed reactions such as restriction enzyme digestion, PCR
- Reaction and Sanger sequencing are carried out by transporting the necessary enzymes and required substrates to the nucleic acid in the microchannel
- the concentrated nucleic acid can be in a suitable buffer
- the voltage is reversed so that the anode is now in the analysis vessel (14) (FIG. 5).
- the microchannel and the buffer vessel (11) are preferably filled beforehand with an aqueous buffer of the above-mentioned composition.
- PCR reactions, CE separations, DNA sequencing, hybridization reactions, mass spectrometric analyzes or molecular biological methods can be carried out.
- the nucleic acid can be analyzed electrophoretically within the microsystem (FIG. 4). As with the elution, the buffer vessel (10) is brought to anodic potential. In a suitable sieving medium, nucleic acid fragments can be separated depending on their size.
- the buffer vessels (10, 11) and the microchannel (1) are filled with a polymer-containing buffer solution.
- a polymer-containing buffer solution are preferably linear soluble polymers, for example acrylamide, polyvinyl alcohol, cellulose (modified and unmodified), dextran or agarose.
- the other buffer composition corresponds to the general composition.
- the virus-containing sample is brought to a pH such that the virus to be examined, or the viruses to be examined, carries a negative excess charge. If necessary, nuclei digestion or virus modifications can be carried out beforehand.
- the suitable buffers have already been described in the general procedure. The pH of the buffer must be well above the pK of the virus. Acid buffers such as sodium citrate are therefore not used, and modification reagents are also not used. Nuclease digestion is preferably carried out by adding RNAses or DNAses
- the benzonase modification reactions for example, are extremely suitable and can be carried out in the form of staining reactions with intercalating dyes (cf. 14) or by incubation with fluorescence-labeled antibodies. In both cases, the choice of dye depends on the type of detection chosen
- the negatively charged viruses are electrophoretically extracted from this buffered solution.
- An electrode is placed in the solution and brought to cationic potential
- the buffer vessel (4) (Fig. 1) is brought to anodic potential and the microchannel (4) is filled with an electrically conductive liquid.
- the composition of the electrolyte corresponds to the general buffer composition.
- the task can be monitored by means of UV or fluorescence a
- the extracted viruses are introduced into the channel using the
- Membrane immobilized and concentrated (Fig. 2) The membrane works according to the principle of large exclusion, the pore size being between 10 and 200 nm depending on the virus
- the viruses concentrated on a few nanoliters can be modified and analyzed in a variety of ways (FIG. 3).
- the open channel system allows the supply and removal of reagents by means of pressure or
- the size exclusion membrane In the case of virus lysis, the size exclusion membrane must be dimensioned so that the target proteins or nucleic acids are also retarded. In principle, any lysis protocol is suitable. Denaturing conditions such as extreme pH values, chaotropic reagents or detergents are preferably used. Examples are dilute sodium hydroxide solution, guanidinium hydrochloride or sodium dodecyl sulfate (SDS). Non-ionic detergents (eg NP-40) can be used to remove the lipoprotein membrane from enveloped viruses
- the concentrated viruses can be eluted in a suitable buffer by applying pressure and / or voltage in a few nanoliters and are available for further analyzes
- the microchannel (1) and the buffer vessel (11) are preferably filled beforehand with an aqueous buffer of the abovementioned composition.
- the viruses can be used, for example, to carry out pathogenicity assays or CE separations. After fractionation on a planar analysis target (14), the viruses can be examined directly using electron microscopy, for example
- the viruses can be analyzed electrophoretically within the microsystem. As with the elution, the buffer vessel (10) is brought to anodic potential (FIG. 4).
- viruses can also be identified by fluorescence spectroscopy using fluorescent labeling methods for proteins or nucleic acids (cf. 1 4 and 3 4) 3. Proteins
- the protein-containing sample is brought to a pH value which is at least one log level next to the pK value of the protein. If the solubility properties of the protein allow, the pH is set below the pK of the protein so that the protein is positively charged. In the following, this case will be discussed. For negatively charged proteins, the voltage relationships are reversed accordingly.
- Suitable buffers meet the general conditions. Alkali-buffered phosphate and citrate buffers are preferably used, e.g. Sodium citrate, 20 mmol / 1, pH 2.5.
- the positively charged proteins are extracted electrophoretically from this buffered solution.
- an electrode is placed in the solution and brought to anionic potential.
- the electrode in the buffer vessel (4) (Fig. 1) is brought to cathodic potential and the microchannel (4) is filled with the buffer.
- the composition of the electrolyte depends on the type of immobilization technique and corresponds to the general conditions.
- a modifier preferably an organic solvent, such as e.g. Methanol between 5 and 30% added.
- the task can be followed in the microchannel (1) by means of UV or fluorescence detection - after prior derivatization.
- ion exchange membranes are also suitable for proteins.
- DEAE phases are preferably used as the soft anion exchanger for negatively charged proteins.
- Quaternary ammonium phases are mainly found as strong anion exchangers Use.
- carboxylic acid phases are suitable as soft exchangers and sulfonic acid phases are suitable as strong exchangers.
- the membranes can be coated with appropriate antibodies and thus enriched for affinity.
- the proteins concentrated on a few nanoliters can be modified and analyzed in many ways (FIG. 3).
- the open channel system allows reagents to be added and removed using pressure or tension.
- the polarity of the voltage becomes the same as for the extraction and
- the protein can be reacted with reactive dyes. It is preferably amine-specific dyes such as e.g. Fluorescein isothiocyanate (FITC).
- FITC Fluorescein isothiocyanate
- the choice of the dye depends primarily on the selected detection unit. For example, FITC is ideal for fluorescence detection after excitation with an argon laser.
- the concentrated proteins can be eluted in a suitable buffer by applying pressure and / or voltage in a few nanoliters and are available for further analyzes.
- the voltage is reversed so that the cathode is now in the analysis vessel (14) (Fig. 5).
- the microchannel and the buffer vessel (11) previously filled with an aqueous buffer of the above composition.
- CE analyzes, mass spectrometric analyzes, enzyme assays, binding studies or immunological processes can be carried out as subsequent analyzes.
- the proteins can be analyzed electrophoretically within the microsystem (FIG. 4).
- Enzyme substrates, fluorescent binding partners or derivatizing reagents, the proteins can also be identified by fluorescence spectroscopy.
- the sample containing bacteria is brought to a pH such that the bacterium to be examined has a negative excess charge. If necessary, nuclease digestion or protein modifications can be carried out beforehand.
- the appropriate buffers have already been described in the general procedure.
- the pH of the buffer must be well above the pK of the bacterium. Acid buffers such as sodium citrate are therefore not used, and modification reagents are also not used.
- Nuclease digests are preferably carried out by adding RNAses or DNAses. Benzonase, for example, is extremely suitable. Modification reactions can be carried out in the form of staining reactions with intercalating dyes (cf. 1.4) or by incubation with fluorescence-labeled antibodies. In both cases, the choice of dye depends on the type of detection chosen. 4.2.
- the negatively charged bacteria are extracted electrophoretically from this buffered solution. For this purpose, an electrode is placed in the solution and brought to cationic potential. The electrode in the
- Buffer vessel (4) (Fig. 1) is brought to anodic potential and the microchannel (4) is filled with an electrically conductive liquid.
- the composition of the electrolyte depends on the type of immobilization technique.
- the task can be followed using UV or fluorescence.
- the extracted bacteria are immobilized and concentrated in the channel with the help of the membrane introduced (FIG. 2).
- the membrane works according to the size exclusion principle (ultrafiltration membrane) or the ion exchanger principle (anion exchanger).
- Membranes are preferably used for sterile filtration with an exclusion size of 0.1-1.45 ⁇ m.
- anion exchangers as for the proteins can also be used (cf. 3.3.)
- the bacteria concentrated on a few nanoliters can, for example, be lyophilized on the membrane and then the proteins or
- Nucleic acids are modified and analyzed in many ways (Fig. 3).
- the open channel system allows reagents to be added and removed using pressure or tension.
- all derivatization methods for proteins and nucleic acids are possible in the microsystem (cf. 1.4 - 1.7 and 3.4 -
- the size exclusion membrane In the case of bacterial lysis, the size exclusion membrane must be dimensioned such that the target proteins or nucleic acids are also retarded.
- any lysis protocol is suitable. Denaturing conditions such as extreme pH values, chaotropic reagents or detergents are preferably used. Examples are dilute sodium hydroxide solution, guanidinium hydrochloride, urea or sodium dodecyl sulfate (SDS). 4.5.
- SDS sodium dodecyl sulfate
- the concentrated bacteria can be eluted in a suitable buffer by applying pressure and / or voltage in a few nanoliters and are available for further analyzes.
- the microchannel (1) and the buffer vessel (11) are preferably filled beforehand with an aqueous buffer of the above-mentioned composition.
- pathogenicity assays or electrophysiological experiments can be carried out with the bacteria, for example.
- the bacteria can, for example, be examined directly by light or electron microscopy, or e.g. can be identified microbiologically on an agar plate via plaques.
- the bacteria can be analyzed electrophoretically within the microsystem (FIG. 4).
- the bacteria can also be identified by fluorescence spectroscopy using fluorescent-labeled antibodies or fluorescent binding partners.
- the process is characterized above all by the simplified isolation and extreme enrichment rates. If the sample is eluted electrophoretically or with pressure from the microchannel, further nanoanalysis methods can then be carried out. After dilution, the isolated sample is also available for conventional macroscopic analysis methods. The method then represents a very efficient sample preparation module for these techniques
- the method can thus replace PCR, for example.
- the method can also be used as a digestion method for viruses, bacteria and other cells.
- bacterial material is isolated, then the bacterium is digested in the microchannel and the released nucleic acid is derivatized and analyzed
- the method can advantageously be used for direct nucleic acid sequencing for diagnostics and research.
- an analysis for hereditary genetic defects, which are caused by deletions, mutations or translocations is possible here.
- Possible areas of use are cystic fibrosis, Down 's Syndrome, sickle cell amia, Huntington 's chorea, hamophilia A and B
- a further application of this nucleic acid analysis is in tumor diagnosis and general recognition for genetic predispositions to certain diseases.
- the analysis of tumor suppressor genes and oncogenes is of particular interest
- nucleic acid amplification methods such as PCR
- the method can also be used for direct gene probe analysis of drug-resistant germs or for subclassification
- the invention also enables the control of genetically engineered products in which freedom from nucleic acids must be guaranteed.
- Proteins can be used for infection diagnosis. Nucleic acids or proteins from fungi or parasites can also be analyzed for these purposes.
- the most important viral representatives in this case are HIV lu. 2, HTLV, HSV, CMV, HPV, hepatitis A, B, C, D, E, F, G, VZV, rotaviruses, EBV and adenoviruses.
- the most important bacterial representatives include chlamydia, mycobacteria, shigella, campylobacter, salmonella, neisserie, staphylococci, streptococci, pneumococci.
- the most important pathogens in fungi are Candida, Aspergillus and Cryptococcus.
- Another area of application is the security monitoring of biological samples.
- the meaning lies here e.g. when checking blood donations and all products made from blood.
- the areas of application largely correspond to those of infection diagnostics.
- this method allows the direct, highly sensitive detection of intact
- Viruses Any, even unknown viruses can be measured directly. This is of enormous importance both for infection diagnosis and for the safety of products made from biological materials, since only special viruses can be detected individually with all other methods.
- the proteins obtained by electrokinetic sample preparation are more easily accessible for subsequent immunodiagnostic analysis due to their enrichment and purification.
- Here have different proteins in human diagnostics such.
- DNA is injected into a microchannel by applying voltage and measured using UV.
- the experiment should show that it is possible to extract nucleic acid electrokinetically.
- the amount of DNA is limited to over 100 mg / 1 by the electric current and not by the DNA concentration. This showed that nucleic acid can be electrokinetically concentrated from a solution over a wide concentration range.
- Table 1 Measurement parameters for electrokinetic nucleic acid injection.
- pBr-DNA was electrokinetically injected into the microchannel and then electrophoretically mobilized in the channel to the anode. There was a UV between the injection end of the channel and the size exclusion membrane in the channel.
- nucleic acid For the concentration of nucleic acid it is necessary to transfer the amount of nucleic acid from a particular solution into the microchannel as quantitatively as possible. If the entire nucleic acid is injected, only a very small amount of nucleic acid should be extractable from the same sample vessel after a 2 injection
- the DNA was stained with the intercalating dye YOYO (Molecular Probes) and detected with laser-induced fluorescence detection (LIF).
- YOYO (0.4 mmol / 1, in 76 ⁇ l TBE buffer) was placed in front of it and mixed with 1-4 ⁇ l of the pBr-DNA solution (1 mg / 1) and incubated at RT for at least 30 min before the measurement.
- the measurement parameters are in Table 3
- the detection profiles were such that after about 10 minutes there was a significant increase in fluorescence, which quickly reached a plateau. After about 30 minutes the fluorescence decreased again, combined with a gradual increase in the current in the channel. The height of the plateau correlated with the amount of DNA. In the second injection, no fluorescence was injected from any of the samples. The data demonstrate the complete extraction of the pBr DNA on the 1st injection. We conclude from the fluorescence course that the entire nucleic acid was completely injected after 30 min.
- Nucleic acid was injected into the microchannel with the membrane installed using the measurement conditions in Table 2.
- pBr-DNA 2.5 mg / 1, 50 ⁇ l
- the separating buffer FIG. 2
- the DNA was not directly detectable.
- the voltage was reversed and the concentrated DNA migrated back through the detector as an intense peak after 12 min.
- Virtually the entire DNA of the 50 ⁇ l sample (0.1 mg) was concentrated in less than 50 nl (1 cm in the capillary). The enrichment factor was therefore a factor of 1000.
- pBr-DNA was electrokinetically injected as described above and immobilized on the membrane (Tab. 2). After immobilization, the tension was not immediately reversed, but that of DNA on the other side of the membrane.
- Bran buffer vessel was replaced with a buffer solution containing cationic intercalating dye (YOYO, 0.4 mmol / 1, Molecular Probes). The tension was maintained for an additional 20 minutes with the dye migrating through the microchannel and through the membrane. The DNA was thus incubated on the membrane with YOYO. The mixture was then electrophoresed for another 10 min without dye in order to remove any remaining YOYO from the capillary. Then the voltage was reversed and the retarded and stained DNA was moved past the detector again.
- YOYO cationic intercalating dye
- the electrokinetically injected DNA migrated through the UV detector after 2 min.
- the UV-VIS spectrum of the injected DNA generated by means of diode array detection (DAD) in the microchannel showed the typical UV spectrum with 2 absorption maxima at 200 and 260 nm. After incubation with YOYO on the membrane, the DNA also showed an absorption maximum at 490 nm. This corresponds exactly to the absorption maximum of the DNA intercalated with YOYO. This proved that macromolecules can be derivatized in the microchannel.
- DAD diode array detection
- Herpes simplex viruses (type 2) were stained with YOYO (Molecular Probes) and detected with laser-induced fluorescence detection (LIF).
- YOYO (0.4 mmol / 1, in 76 ⁇ l TBE buffer) was introduced and 4 ⁇ l of the HSV-2 solution (5 ⁇ 10 5 viruses / ml) were added and incubated at RT for at least 30 min before the measurement.
- the measurement parameters are in Table 3.
- the few injected, intercalated viruses (10-20) were detected as individual signals. To identify the signals, the same sample was compared under The electrophoresis conditions on a Prince-CE (Lauerlabs) were analyzed with a nanofraction collector (Probot, BAI-Instruments). The end of the microchannel was fractionated in a time-controlled manner on different electron microscopy carriers and examined in the EM after negative contrasting with uranyl acetate.
- FIG. 1 Schematic representation of the purification apparatus
- a microchannel (1) with a built-in membrane (2) connects 2 buffer vessels (3,4). These buffer vessels can be brought to different voltage potentials by means of electrodes (5) )
- the sample to be examined is in (3)
- Fig. 2 Schematic representation of the concentration.
- the macromolecule to be investigated was electrokinetically injected into the microchannel (1) with the membrane (2) installed.
- the sample vessel was already replaced by the concentration buffer (7).
- the macromolecules migrate to the membrane and are held there
- Fig. 3 Schematic representation of the sample modification In the reaction vessels (8,9) are the derivatization reagents, which are brought either electrokinetically and / or with the help of pressure to the concentrated macromolecules
- Fig. 4 Schematic representation of an on-line analysis method.
- the concentrated and modified macromolecule becomes electrokinetic mobilized in the microchannel (1) past a detector window (12) so that the spectroscopic properties can be analyzed and evaluated (13).
- Fig. 5 Schematic representation of the fractionation of the purified
- the concentrated sample is collected in the sample vessel or on the analysis target (14) and is available for further analysis.
- Fig. 6 Schematic representation of the high-throughput purification apparatus.
- a variety of microchannels are arranged to be compatible with the sample format (e.g. microtiter plate).
- the membrane (2) is introduced over the entire format and connected to a second microchannel array (15). The procedure of these multiple arrangements corresponds to Fig. 1-5.
- Fig. 7 Schematic representation of the enrichment apparatus for fast
- Fig. 8 Schematic representation of the rapid enrichment from saline
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Saccharide Compounds (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97954757A EP0958300A1 (fr) | 1997-01-08 | 1997-12-24 | Preparation electrocinetique d'echantillons |
AU59857/98A AU5985798A (en) | 1997-01-08 | 1997-12-24 | Electrokinetic sample preparation |
JP53051098A JP2001509258A (ja) | 1997-01-08 | 1997-12-24 | 界面動電的サンプル調製法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1997100364 DE19700364A1 (de) | 1997-01-08 | 1997-01-08 | Elektrokinetische Probenvorbereitung |
DE19700364.8 | 1997-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998030571A1 true WO1998030571A1 (fr) | 1998-07-16 |
Family
ID=7816953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/007306 WO1998030571A1 (fr) | 1997-01-08 | 1997-12-24 | Preparation electrocinetique d'echantillons |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0958300A1 (fr) |
JP (1) | JP2001509258A (fr) |
AU (1) | AU5985798A (fr) |
DE (1) | DE19700364A1 (fr) |
WO (1) | WO1998030571A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000146911A (ja) * | 1998-08-04 | 2000-05-26 | Ortho Clinical Diagnostics Inc | 核酸を分離する方法 |
WO2004081530A2 (fr) * | 2003-03-10 | 2004-09-23 | The Johns Hopkins University | Procede et appareil pour la surveillance et la bioprospection de l'environnement |
JP2004537033A (ja) * | 2001-02-22 | 2004-12-09 | プラント・バイオサイエンス・リミテッド | 荷電化合物の単離方法 |
US8361716B2 (en) | 2008-10-03 | 2013-01-29 | Pathogenetix, Inc. | Focusing chamber |
US8685708B2 (en) | 2012-04-18 | 2014-04-01 | Pathogenetix, Inc. | Device for preparing a sample |
US8999636B2 (en) | 2007-01-08 | 2015-04-07 | Toxic Report Llc | Reaction chamber |
US12179188B2 (en) | 2020-06-17 | 2024-12-31 | Entegris, Inc. | Ion-exchange membranes, filters, and methods |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10149875A1 (de) * | 2001-10-10 | 2003-07-03 | Alpha Technology Ges Fuer Ange | Vorrichtung zur Extraktion elektrisch geladener Moleküle |
GB2416030B (en) * | 2004-01-28 | 2008-07-23 | Norchip As | A diagnostic system for carrying out a nucleic acid sequence amplification and detection process |
DE102006002258B4 (de) | 2006-01-17 | 2008-08-21 | Siemens Ag | Modul zur Aufbereitung einer biologischen Probe, Biochip-Satz und Verwendung des Moduls |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005390A1 (fr) * | 1991-08-28 | 1993-03-18 | Guzman Norberto A | Appareil d'electrophorese capillaire automatique |
-
1997
- 1997-01-08 DE DE1997100364 patent/DE19700364A1/de not_active Withdrawn
- 1997-12-24 EP EP97954757A patent/EP0958300A1/fr not_active Withdrawn
- 1997-12-24 WO PCT/EP1997/007306 patent/WO1998030571A1/fr not_active Application Discontinuation
- 1997-12-24 AU AU59857/98A patent/AU5985798A/en not_active Abandoned
- 1997-12-24 JP JP53051098A patent/JP2001509258A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005390A1 (fr) * | 1991-08-28 | 1993-03-18 | Guzman Norberto A | Appareil d'electrophorese capillaire automatique |
Non-Patent Citations (1)
Title |
---|
BOROVETZ, HARVEY S. ET AL: "Protein adsorption in vitro onto biomaterial surfaces covered with ULTI carbon", BIOMATER., MED. DEVICES, ARTIF. ORGANS (1982), 10(3), 187-203 CODEN: BMDOAI;ISSN: 0090-5488, 1982, XP002060277 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000146911A (ja) * | 1998-08-04 | 2000-05-26 | Ortho Clinical Diagnostics Inc | 核酸を分離する方法 |
JP4531888B2 (ja) * | 1998-08-04 | 2010-08-25 | オルソ−クリニカル ダイアグノスティクス,インコーポレイティド | 核酸を分離する方法 |
JP2004537033A (ja) * | 2001-02-22 | 2004-12-09 | プラント・バイオサイエンス・リミテッド | 荷電化合物の単離方法 |
WO2004081530A2 (fr) * | 2003-03-10 | 2004-09-23 | The Johns Hopkins University | Procede et appareil pour la surveillance et la bioprospection de l'environnement |
WO2004081530A3 (fr) * | 2003-03-10 | 2005-01-27 | Univ Johns Hopkins | Procede et appareil pour la surveillance et la bioprospection de l'environnement |
US8999636B2 (en) | 2007-01-08 | 2015-04-07 | Toxic Report Llc | Reaction chamber |
US8361716B2 (en) | 2008-10-03 | 2013-01-29 | Pathogenetix, Inc. | Focusing chamber |
US8685708B2 (en) | 2012-04-18 | 2014-04-01 | Pathogenetix, Inc. | Device for preparing a sample |
US12179188B2 (en) | 2020-06-17 | 2024-12-31 | Entegris, Inc. | Ion-exchange membranes, filters, and methods |
Also Published As
Publication number | Publication date |
---|---|
AU5985798A (en) | 1998-08-03 |
JP2001509258A (ja) | 2001-07-10 |
EP0958300A1 (fr) | 1999-11-24 |
DE19700364A1 (de) | 1998-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60010058T2 (de) | Biochemische reinigungsgeräte mit immobilisierten fangsonden und ihre anwendungen | |
DE69737071T2 (de) | Integrierte mikrofluidische vorrichtungen | |
EP1056758B1 (fr) | Technique de purification d'acide nucleique par electrophorese | |
KR100779138B1 (ko) | 용액 캡쳐에 의한 질량 분광측정법으로 연속 분석하기 위한핵산의 신속 정제 방법 | |
EP2215103B1 (fr) | Procédé de purification d'acides nucléiques | |
AU725433B2 (en) | Apparatus and methods for active biological sample preparation | |
CN102888394B (zh) | 核酸提取方法和核酸提取筒 | |
EP1027596A1 (fr) | Dispositif d'electrophorese microfabrique a arrangement capillaire et son procede d'utilisation | |
KR20100001826A (ko) | 핵산 추출 장치 | |
EP2084280A1 (fr) | Dispositif microfluidique intégré pour la purification de molécules d'analyte et procédé de purification | |
DE4438833A1 (de) | Verfahren zur analytischen Trennung von Viren | |
EP1411340A2 (fr) | Dispositifs biochimiques de purification au moyen de sondes de capture et leurs utilisations | |
US10750928B2 (en) | Simultaneous extraction and separation of RNA and DNA from single cells using electrophoretic techniques | |
WO2002042500A2 (fr) | Appareil et procede pour la concentration electrophoretique sur micropoint | |
WO1998030571A1 (fr) | Preparation electrocinetique d'echantillons | |
EP2700712B1 (fr) | Procédé pour l'électrophorèse d'acides nucléiques, procédé pour concentrer et purifier des acides nucléiques, cartouche pour l'électrophorèse d'acide nucléique, et procédé pour produire une cartouche pour l'électrophorèse d'acide nucléique | |
DE102012219156A1 (de) | Integriertes mikrofluidisches bauteil zur anreicherung und extraktion biologischer zellbestandteile | |
US20140251809A1 (en) | Apparatus for preparing nucleic acids and method for preparing nucleic acids | |
US20240327818A1 (en) | Methods and devices for isolating rna using epitachophoresis | |
US20240318164A1 (en) | Methods and devices for nucleic acid extraction using epitachophoresis | |
EP3502275B1 (fr) | Procédé d'enrichissement des acides nucléiques | |
Paxon et al. | 1 Separations in Multiple-Channel Microchips | |
Root | Novel polymers and electrophoretic methods for biomolecule purification and separation | |
AU5197000A (en) | Method for selective isolation of desired charged biological materials from undesired charged materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997954757 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 530510 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09341227 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997954757 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997954757 Country of ref document: EP |